This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zealand Announces Dosing Initiation in Type 2 Diabetes Study
by Zacks Equity Research
Zealand's (ZEAL) partner, Boehringer Ingelheim, is developing BI 456906, a long-acting GLP-1/glucagon dual agonist, as a treatment for obesity and type 2 diabetes.
Geron's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Geron.
Is Geron (GERN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GERN) Outperforming Other Medical Stocks This Year?
Dynavax's Partner Doses First Patient in Coronavirus Study
by Zacks Equity Research
Dynavax's (DVAX) China-based partner initiates dosing in a phase I study evaluating a COVID-19 vaccine using the company's proprietary CpG 1018 adjuvant. Preliminary data are expected in August.
Implied Volatility Surging for Geron Corporation (GERN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Geron Corporation (GERN) stock based on the movements in the options market lately.
Moving Average Crossover Alert: Geron
by Zacks Equity Research
Geron Corporation (GERN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Dynavax Closes Enrollment in Renal Disease Study on Heplisav-B
by Zacks Equity Research
Dynavax (DVAX) is developing its hepatitis B vaccine, Heplisav-B, in patients with end-stage renal disease undergoing hemodialysis in a phase I study.
How Geron Corporation (GERN) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Geron Corporation (GERN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Top Ranked Momentum Stocks to Buy for June 9th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 9th.
Is Geron (GERN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (GERN) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for June 5th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 5th.
Top Ranked Momentum Stocks to Buy for June 2nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 2nd.
Geron (GERN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Geron (GERN) delivered earnings and revenue surprises of 11.11% and -52.73%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Geron (GERN) Q1 Earnings Expected to Decline
by Zacks Equity Research
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Geron's (GERN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Geron (GERN) reports encouraging fourth-quarter 2019 results. Operating expenses increase on a year-over-year basis.
Geron (GERN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Geron (GERN) delivered earnings and revenue surprises of 25.00% and 26.67%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Geron (GERN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios' Tibsovo Wins FDA's Breakthrough Therapy Tag for MDS
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy status on Agios' (AGIO) leukemia drug Tibsovo for treating relapsed/refractory myelodysplastic syndrome in adult patients with a susceptible IDH1 mutation.
Geron (GERN) Up 2.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Geron (GERN) Stock Surges 40% YTD: What's Driving the Rally?
by Zacks Equity Research
Geron's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two clinical studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
Geron (GERN) Q3 Earnings Beat Estimates, Stock Gains 4.1%
by Zacks Equity Research
Geron (GERN) reports encouraging third-quarter 2019 results. Operating expenses increase on a year-over-year basis.
Earnings Preview: Geron (GERN) Q3 Earnings Expected to Decline
by Zacks Equity Research
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Geron Starts Enrollment in Phase III MDS Study on Imetelstat
by Zacks Equity Research
Geron enrolls first patient in the late-stage IMerge study to evaluate imetelstat in myelodysplastic syndromes.
Geron's Imetelstat Gets Fast Track Status for Myelofibrosis
by Zacks Equity Research
Geron's (GERN) sole pipeline candidate, imetelstat, receives Fast Track designation from the FDA for treating relapsed or refractory myelofibrosis. Shares up.
Why Is Geron (GERN) Up 21.7% Since Last Earnings Report?
by Zacks Equity Research
Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.